New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - acarbose 100mg;   - tablet - 100 mg - active: acarbose 100mg   excipient: colloidal silicon dioxide magnesium stearate microcrystalline cellulose pregelatinised maize starch - indicated for the additional treatment of insulin dependent and non-insulin dependent diabetes mellitus in association with diet.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - acarbose 50mg;   - tablet - 50 mg - active: acarbose 50mg   excipient: colloidal silicon dioxide magnesium stearate microcrystalline cellulose pregelatinised maize starch - indicated for the additional treatment of insulin dependent and non-insulin dependent diabetes mellitus in association with diet.

Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - aprotinin - solution for injection - aprotinin 500,000/50 kiu/ml - antihemorrhagics

Malta - English - Medicines Authority

miller and miller chemicals unit 3, burnside industrial est, 49-53 roebuck road hainault, essex ig63ug, united kingdom - aprotinin - solution for injection - aprotinin 10,000 kiu/ml - antihemorrhagics

Malta - English - Medicines Authority

cherubino limited delf building, sliema road, gzira, gzr 1637, malta - aprotinin - solution for injection - aprotinin 100000 kiu/ml - antihemorrhagics

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - apixaban, quantity: 2.5 mg - tablet, film coated - excipient ingredients: lactose; sodium lauryl sulfate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow - eliquis is indicated for the prevention of venous thromboembolic events (vte) in adult patients who have undergone elective total hip or total knee replacement surgery.,eliquis is indicated for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke.,eliquis is indicated for the treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe) in adult patients.,eliquis is indicated for the prevention of recurrent dvt and pe in adult patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - rivaroxaban, quantity: 10 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; sodium lauryl sulfate; croscarmellose sodium; hypromellose; lactose monohydrate; iron oxide red; titanium dioxide; macrogol 3350; magnesium stearate - xarelto is indicated for: ? prevention of venous thromboembolism (vte) in adult patients who have undergone major orthopaedic surgery of the lower limbs (elective total hip replacement, treatment for up to 5 weeks; elective total knee replacement, treatment for up to 2 weeks) ? prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke ? treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe) and for the prevention of recurrent dvt and pe,xarelto, in combination with aspirin, is indicated for ? the prevention of major cardiovascular events (composite of stroke, myocardial infarction and cardiovascular death) in patients with coronary artery disease (cad) and/or peripheral artery disease (pad).

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - apixaban, quantity: 5 mg - tablet, film coated - excipient ingredients: sodium lauryl sulfate; microcrystalline cellulose; lactose; purified water; magnesium stearate; croscarmellose sodium; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide red - eliquis is indicated for the prevention of venous thromboembolic events (vte) in adult patients who have undergone elective total hip or total knee replacement surgery.,eliquis is indicated for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke.,eliquis is indicated for the treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe) in adult patients.,eliquis is indicated for the prevention of recurrent dvt and pe in adult patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - rivaroxaban, quantity: 20 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; hypromellose; lactose monohydrate; magnesium stearate; sodium lauryl sulfate; iron oxide red; macrogol 3350; titanium dioxide - xarelto is indicated for: ? prevention of venous thromboembolism (vte) in adult patients who have undergone major orthopaedic surgery of the lower limbs (elective total hip replacement, treatment for up to 5 weeks; elective total knee replacement, treatment for up to 2 weeks) ? prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke ? treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe) and for the prevention of recurrent dvt and pe,xarelto, in combination with aspirin, is indicated for ? the prevention of major cardiovascular events (composite of stroke, myocardial infarction and cardiovascular death) in patients with coronary artery disease (cad) and/or peripheral artery disease (pad).

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - rivaroxaban, quantity: 15 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; hypromellose; lactose monohydrate; magnesium stearate; sodium lauryl sulfate; iron oxide red; macrogol 3350; titanium dioxide - xarelto is indicated for: ? prevention of venous thromboembolism (vte) in adult patients who have undergone major orthopaedic surgery of the lower limbs (elective total hip replacement, treatment for up to 5 weeks; elective total knee replacement, treatment for up to 2 weeks) ? prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke ? treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe) and for the prevention of recurrent dvt and pe,xarelto, in combination with aspirin, is indicated for ? the prevention of major cardiovascular events (composite of stroke, myocardial infarction and cardiovascular death) in patients with coronary artery disease (cad) and/or peripheral artery disease (pad).